Skip to main content
. 2016 Jun 16;26:16030. doi: 10.1038/npjpcrm.2016.30

Figure 2.

Figure 2

Comparison of reduction in the rate of moderate/severe exacerbations with BDP/FF versus formoterol in COPD patients. Adapted from FORWARD study: all patients (Wedzicha et al. 28) and data pooling from post hoc analysis on baseline blood eosinophil count (Siddiqui et al. 35). BDP/FF, beclometasone dipropionate/formoterol. 20% is the suggested minimal clinically important difference for exacerbations.47